[go: up one dir, main page]

LT4025188T - Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis - Google Patents

Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis

Info

Publication number
LT4025188T
LT4025188T LTEPPCT/EP2021/062147T LTEP2021062147T LT4025188T LT 4025188 T LT4025188 T LT 4025188T LT EP2021062147 T LTEP2021062147 T LT EP2021062147T LT 4025188 T LT4025188 T LT 4025188T
Authority
LT
Lithuania
Prior art keywords
extended release
dosing regimens
injectable formulations
regimens associated
release paliperidone
Prior art date
Application number
LTEPPCT/EP2021/062147T
Other languages
English (en)
Inventor
Srihari Gopal
Raja Venkatasubramanian
Huybrecht T'jollyn
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4025188(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LT4025188T publication Critical patent/LT4025188T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/EP2021/062147T 2020-11-30 2021-05-07 Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis LT4025188T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (1)

Publication Number Publication Date
LT4025188T true LT4025188T (lt) 2024-03-12

Family

ID=75888043

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2021/062147T LT4025188T (lt) 2020-11-30 2021-05-07 Dozavimo režimai susiję su prailginto atpalaidavimo paliperidono injekcinėmis vaisto formomis

Country Status (21)

Country Link
US (2) US11304951B1 (lt)
EP (2) EP4356966A3 (lt)
KR (2) KR102794804B1 (lt)
CN (1) CN116583270A (lt)
AU (2) AU2021386450B2 (lt)
CA (1) CA3203566A1 (lt)
DK (1) DK4025188T3 (lt)
ES (1) ES2973583T3 (lt)
FI (1) FI4025188T3 (lt)
HR (1) HRP20240074T1 (lt)
HU (1) HUE065573T2 (lt)
IL (1) IL303253A (lt)
LT (1) LT4025188T (lt)
MX (2) MX2023006366A (lt)
PL (1) PL4025188T3 (lt)
PT (1) PT4025188T (lt)
RS (1) RS65178B1 (lt)
SI (1) SI4025188T1 (lt)
SM (1) SMT202400077T1 (lt)
TW (1) TWI877363B (lt)
WO (1) WO2022111859A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025187B1 (en) 2020-11-30 2024-01-03 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
IL303252A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
CA3203567A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
AU2008340101C1 (en) * 2007-12-19 2025-03-06 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
EP2493473A1 (en) 2009-10-30 2012-09-05 Janssen Pharmaceutica NV Dosing regimen associated with long-acting injectable paliperidone esters
EP2529757B1 (en) 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
FI3744326T3 (fi) 2015-04-07 2024-02-02 Janssen Pharmaceutica Nv Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille
PT3723760T (pt) * 2017-12-14 2025-08-05 SpecGx LLC Processo de moagem de um só passo para preparar ésteres de paliperidona micronizados
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Also Published As

Publication number Publication date
ES2973583T3 (es) 2024-06-20
RS65178B1 (sr) 2024-03-29
US11304951B1 (en) 2022-04-19
IL303253A (en) 2023-07-01
MX2024009188A (es) 2024-08-06
DK4025188T3 (da) 2024-03-04
AU2021386450A9 (en) 2025-03-13
HUE065573T2 (hu) 2024-06-28
KR102794804B1 (ko) 2025-04-10
PL4025188T3 (pl) 2024-06-17
US20220249495A1 (en) 2022-08-11
KR20250053980A (ko) 2025-04-22
MX2023006366A (es) 2023-08-07
CN116583270A (zh) 2023-08-11
JP2023552329A (ja) 2023-12-15
EP4356966A3 (en) 2024-07-17
HRP20240074T1 (hr) 2024-03-29
TW202222319A (zh) 2022-06-16
AU2021386450B2 (en) 2024-03-21
FI4025188T3 (fi) 2024-02-21
TWI877363B (zh) 2025-03-21
SMT202400077T1 (it) 2024-03-13
EP4025188A1 (en) 2022-07-13
CA3203566A1 (en) 2022-06-02
AU2024204213A1 (en) 2024-07-11
AU2021386450A1 (en) 2023-07-13
EP4025188B1 (en) 2024-01-10
SI4025188T1 (sl) 2024-03-29
KR20230116013A (ko) 2023-08-03
PT4025188T (pt) 2024-02-29
EP4356966A2 (en) 2024-04-24
WO2022111859A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
HUE065573T2 (hu) Elnyújtott felszabadulású paliperidon injektálható készítményeihez kapcsolódó adagolási rendek
HUE065387T2 (hu) Nyújtott hatóanyagleadású paliperidon injektálható készítményekkel kapcsolatos adagolási rendek
IL311134A (en) Dosing regimens associated with delayed-release paliperidone injection formulations
LT4025189T (lt) Dozavimo režimai, susiję su prailginto atpalaidavimo paliperidono palmitato injekcinėmis vaisto formomis
AU2021387679A9 (en) Dosing regimens associated with extended release paliperidone injectable formulations
HUE068716T2 (hu) Injektálható készítmény
LT2234617T (lt) Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
IL314891B1 (en) Dosage regimens and related compositions and methods
IL324059A (en) Dosing regimen for missed doses of long-acting injectable paliperidone esters
BR112012010195A2 (pt) regime de dosagem associado a ésteres de paliperidona injetável de longa ação
PL3347054T3 (pl) Schematy dawkowania koniugatów przeciwciało anty-TF-lek
PL3638373T3 (pl) Schematy dawkowania dla podawania ADC anty-CD19
ZA202005772B (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
IL233485A0 (en) History of spiroindoline as gonadotropin-releasing hormone receptor antagonists
SG10201607680RA (en) A height accessible working platform with horizontally displaceable cradle
HK40078122A (en) Dosing regimens associated with extended release paliperidone injectable formulations
IL279214A (en) Therapeutic dosage regimens comprising adherent stromal cells
IL308095A (en) Dosing regimens
HUP2100259A1 (hu) Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
ZA201508209B (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists